Anticoagulants Industry Growth Analysis and Forecasts To 2021 Anticoagulants Industry: 2017 Global Market Trend | Page 2

Global Anticoagulants Industry 2017 Market Growth, Trends and Demands
Research Report
Global Anticoagulants Market has increased over the years and is expected to grow in the next four years
i.e. 2017-2021, particularly due to development of novel oral anticoagulants (NOACs). The global
anticoagulants market is supported by various growth drivers such as growing aging population, rising
prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants,
etc.
Company Coverage: Bayer Group, BMS/Pfizer, Boehringher Ingelheim, Daiichi Sankyo.
Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood
from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart,
veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to
treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC)
and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by
interrupting the process involved in the formation of blood clots.
The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available
and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa),
apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken as
tablets or capsules. There's also an anticoagulant called heparin that can be given by injection.
Complete report available at http://www.marketreportsonline.com/587071.html